NEW YORK, July 24, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ : PDLI ), Arena Pharmaceuticals Inc. (NASDAQ : ARNA ), StemCells Inc. (NASDAQ : STEM ), Northwest Biotherapeutics Inc. (NASDAQ : NWBO ), and Acorda Therapeutics Inc. (NASDAQ : ACOR ). Free research report on PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PDL BioPharma Inc.'s stock finished Thursday's session 1.28% lower at $6.18. A total of 2.02 million shares were traded, which was below its three months average volume of 2.79 million shares. Over the last one month and the previous three months, PDL BioPharma Inc.'s shares have declined 7.07% and 11.08%, respectively. Additionally, the stock has plummeted 16.21% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 3.51% and 11.26%, respectively. PDL BioPharma Inc.'s stock traded at a PE ratio of 3.24 and has a Relative Strength Index (RSI) of 41.39. Sign up and read the free notes on PDLI at:
On Thursday, shares in Arena Pharmaceuticals Inc. ended the session 2.35% lower at $4.15. The stock reported a trading volume of 1.96 million shares, below its three months average volume of 2.77 million shares. Arena Pharmaceuticals Inc.'s shares have lost 7.37% in the last one month and 6.53% in the previous three months. However, the stock has gained 19.60% on YTD basis. The company is trading 4.03% below its 50-day moving average and 4.67% below its 200-day moving average. Moreover, shares of Arena Pharmaceuticals Inc. have an RSI of 42.44. The complimentary notes on ARNA can be downloaded in PDF format at:
StemCells Inc.'s stock declined 5.75%, to close the day at $0.49. The stock recorded a trading volume of 1.40 million shares, below its three months average volume of 2.53 million shares. Over the last one month and over the past three months, StemCells Inc.'s shares have plummeted 31.93% and 40.23%, respectively. Furthermore, the stock has lost 47.86% since the start of this year. The company's shares are trading 21.26% below their 50-day moving average. Additionally, StemCells Inc. has an RSI of 32.05. Register for free on Equity Research Institute and access the latest research on STEM at:
On Thursday, shares in Northwest Biotherapeutics Inc. recorded a trading volume of 0.73 million shares, higher than their three months average volume of 0.60 million shares. The stock ended the day 1.83% higher at $12.24. Northwest Biotherapeutics Inc.'s stock has surged 19.18% in the last one month, 42.00% in the previous three months and 128.79% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 25.99% and 70.06%, respectively. Furthermore, shares of Northwest Biotherapeutics Inc. have an RSI of 78.69. The complete research on NWBO is available for free at:
Acorda Therapeutics Inc.'s stock lost 1.36%, to close Thursday's session at $34.75. The stock recorded a trading volume of 0.26 million shares, below its three months average volume of 0.60 million shares. Over the last one month and since the start of this year, Acorda Therapeutics Inc.'s shares have fallen by 0.34% and 14.97%, respectively. However, the stock has gained 3.73% in the previous three months. The company is trading 6.83% above its 50-day moving average. Furthermore, Acorda Therapeutics Inc.'s stock traded at a PE ratio of 105.30 and has an RSI of 55.70. Free in-depth research on ACOR is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.